Enterprise Trust & Investment’s AstraZeneca AZN Stock Holding History

Enterprise Trust & Investment’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$7K	Buy	+50	New	+$6.56K	﹤0.01%	243

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Enterprise Trust & Investment's AZN Position: Q2 2022 in Review

Enterprise Trust & Investment opened a new position in AstraZeneca (AZN) in Q2 2022: 50 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #243 among its holdings.

1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Enterprise Trust & Investment held 50 shares of AstraZeneca worth $7K as of Q2 2022.
AstraZeneca was a new Enterprise Trust & Investment position in Q2 2022.
AstraZeneca made up ﹤0.01% of Enterprise Trust & Investment's portfolio in Q2 2022, its #243 holding.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Enterprise Trust & Investment's 13F filing for Q2 2022, filed 22 Jul 2022.